ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1672

Facilitating the Medication Decision-Making process—What Do Patients with Lupus Nephritis Say?

Ricahrd Shewchuk1, Haiyan Qu2, W. Winn Chatham2, Jinoos Yazdany3, Maria Dall'era4 and Jasvinder A. Singh5, 1University fo Alabama at Birmingham, Birmingham, AL, 2University of Alabama at Birmingham, Birmingham, AL, 3Medicine, University of California, San Francisco, San Francisco, CA, 4Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, 5University of Alabama and VA Medical Center, Birmingham, AL

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: African-Americans, Hispanic patients, Lupus nephritis, medical management and qualitative

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Lupus Erythematosus - Clinical Aspects and Treatment: Biomarker, Translational and Nephritis Studies

Session Type: Abstract Submissions (ACR)

Background/Purpose: Low medication adherence in lupus nephritis puts patients at risk for poor outcomes, but to our knowledge, relatively little is known about what patients perceive as facilitative factors in medication decisional processes. Our objective was to comprehensively identify factors that racial/ethnic minority patients with lupus perceive as facilitating decisions to take their lupus medications as prescribed.

Methods: We conducted 8 Nominal Group Technique (NGT) meetings with patients with lupus nephritis who received treatment from lupus clinics at University of Alabama at Birmingham (UAB) and University of California at San Francisco (UCSF). Patient perceptions of facilitators influencing the medication decision-making outcome were generated by asking the following question: “What sorts of things make it easier for people to decide to take the medications that doctors prescribe for treating their lupus kidney disease?” Patients in each NGT meeting prioritized a subset of facilitative factors in terms of importance using a voting procedure.  To obtain an aggregated result, responses with the same or very similar wording generated by different groups were combined and the voting totals for all prioritized responses were summed across groups.

Results: 52 patients with lupus nephritis participated in 8 NGT meetings: 27 African Americans (4 nominal groups), 13 Hispanic (2 nominal groups) and 12 Caucasian (2 nominal groups). Mean age was 40.6 years (SD=13.3), disease duration was 11.8 years (SD=8.3), 34.6% had education level of college or greater, 55.8% needed help with reading health materials, indicating low health literacy. The participants generated 281 responses (range=26-42 responses/meeting). 36% of all responses were endorsed across all groups by patients as relatively more important than others in facilitating decisions to take prescribed medications (range=31-52% of endorsed facilitators/total). More variation in the level of agreement about the importance of specific facilitators was observed with African American patients (range 31-52%) than with Caucasian (32-37%) and Hispanic patients (31-34%).  Overall, participants allocated about 57% of the available votes from all groups as an endorsement of perceived importance to 8 facilitators that can be briefly summarized as: demonstrated efficacy, longevity expectations, symptom relief, expectations for living a more normal life, family, cost and affordability, awareness of potential risks and benefits, and minimal side effects.

Conclusion: A general consistency of factors perceived to facilitate medication decision making by lupus nephritis patients was noted across ethnic/racial groups. Patient-identified facilitators of lupus medication adherence can inform the design of effective educational materials for patients with lupus nephritis.


Disclosure:

R. Shewchuk,
None;

H. Qu,
None;

W. W. Chatham,
None;

J. Yazdany,
None;

M. Dall’era,
None;

J. A. Singh,

takeda, savient,

2,

takeda, savient, regeneron, allergan,

5.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/facilitating-the-medication-decision-making-process-what-do-patients-with-lupus-nephritis-say/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology